Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05799079 | Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant | terminated | Phase 2 | 1 | Sanjay MohanOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT03760523 | Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 7, 2026 |
| NCT04240002 | A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 9 | Astellas Pharma Global Development, Inc.INDUSTRY | 5 | Jan 5, 2026 | clinicaltrials |
| NCT03055286 | Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | terminated | Phase 1 / Phase 2 | 15 | JW PharmaceuticalINDUSTRY | 2 | Dec 26, 2025 | clinicaltrials |
| NCT05361057 | Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients | terminated | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05127174 | Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms | terminated | Phase 1 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07004816 | The Mutation Profile and Prognosis in AML With IDH1/2 Mutation | terminated | — | 1,015 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04937166 | A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies | terminated | Phase 1 | 25 | Kahr MedicalINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT00776373 | Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies(UPCC 25406) | terminated | Phase 1 / Phase 2 | 4 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT04874194 | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | terminated | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT04511130 | Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant(ARTEMIS) | terminated | Phase 2 | 92 | Marker Therapeutics, Inc.INDUSTRY | 1 | Oct 30, 2025 | clinicaltrials |
| NCT00726232 | Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia | terminated | Phase 2 | 73 | Incyte CorporationINDUSTRY | 2 | Oct 29, 2025 | clinicaltrials |
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | terminated | Phase 3 | 252 | Incyte CorporationINDUSTRY | 17 | Oct 21, 2025 | clinicaltrials |
| NCT04623216 | Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. | terminated | Phase 1 / Phase 2 | 24 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 16, 2025 | clinicaltrials |
| NCT04678336 | CD123 Redirected T Cells for AML in Pediatric Subjects | terminated | Phase 1 | 12 | University of PennsylvaniaOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT03940352 | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) | terminated | Phase 1 | 52 | Novartis PharmaceuticalsINDUSTRY | 7 | Oct 10, 2025 | clinicaltrials |
| NCT04702425 | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) | terminated | Phase 1 | 37 | Novartis PharmaceuticalsINDUSTRY | 9 | Oct 10, 2025 | clinicaltrials |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | terminated | Phase 3 | 177 | Incyte CorporationINDUSTRY | 19 | Oct 2, 2025 | clinicaltrials |
| NCT05358808 | ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)(ACHIEVE) | terminated | Phase 2 | 16 | TC BiopharmINDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05961839 | Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | terminated | Phase 1 | 66 | Schrödinger, Inc.INDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT03860844 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia(ISAKIDS) | terminated | Phase 2 | 67 | SanofiINDUSTRY | 16 | Sep 9, 2025 | clinicaltrials |
| NCT02438761 | PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)(5) | terminated | Phase 2 | 10 | Institut CurieOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT03769532 | MRD-guided Treatment in NPM1mut AML Patients(PEMAZA) | terminated | Phase 2 | 26 | Technische Universität DresdenOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | terminated | Phase 1 / Phase 2 | 24 | Sutro Biopharma, Inc.INDUSTRY | 9 | Aug 24, 2025 | clinicaltrials |
| NCT06508489 | A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies | terminated | Phase 1 / Phase 2 | 7 | SanofiINDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT05817058 | First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 30 | Affimed GmbHINDUSTRY | 2 | Jul 23, 2025 | clinicaltrials |
| NCT04789408 | Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 15 | Kite, A Gilead CompanyINDUSTRY | 2 | Jul 11, 2025 | clinicaltrials |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | terminated | Phase 2 | 31 | Roswell Park Cancer InstituteOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT01688011 | Connect® Myeloid Disease Registry | terminated | — | 2,013 | CelgeneINDUSTRY | 2 | Jul 3, 2025 | clinicaltrials |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | terminated | Phase 1 | 55 | Biomea Fusion Inc.INDUSTRY | 5 | Jul 3, 2025 | clinicaltrials |
| NCT04103645 | Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients | terminated | Phase 2 | 2 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT05442580 | CART-38 in Adult AML and MM Patients | terminated | Phase 1 | 11 | University of PennsylvaniaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT03724084 | Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement | terminated | Phase 1 / Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06128044 | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia(AMpLify) | terminated | Phase 1 | 12 | Caribou Biosciences, Inc.INDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT01751425 | Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors | terminated | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04789655 | Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 45 | CelgeneINDUSTRY | 3 | May 31, 2025 | clinicaltrials |
| NCT06449482 | Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03537599 | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 4 | Sumithira VasuOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT05447663 | A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 8 | Novartis PharmaceuticalsINDUSTRY | 3 | May 16, 2025 | clinicaltrials |
| NCT03286114 | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab | terminated | Phase 1 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT03576547 | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT05038644 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia | terminated | Phase 1 | 22 | Ehab L AtallahOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives | terminated | Phase 2 | 4 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04185428 | Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia | terminated | N/A | 9 | University of FloridaOTHER | 1 | Apr 7, 2025 | clinicaltrials |
| NCT03038230 | MCLA-117 in Acute Myelogenous Leukemia | terminated | Phase 1 | 80 | Merus B.V.INDUSTRY | 5 | Apr 6, 2025 | clinicaltrials |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors | terminated | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT05079230 | Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia(ENHANCE-3) | terminated | Phase 3 | 378 | Gilead SciencesINDUSTRY | 20 | Apr 4, 2025 | clinicaltrials |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | terminated | Phase 1 | 272 | IGM Biosciences, Inc.INDUSTRY | 5 | Mar 28, 2025 | clinicaltrials |
| NCT03746054 | Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality(PALERMO) | terminated | Phase 3 | 80 | University Hospital, AngersOTHER_GOV | 1 | Mar 17, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jan 9, 2026source: clinicaltrials